TOP2A and neoplasm: Press et al. [24] considered the association of TOP2A amplification and improved PFS or DFS with anthracycline-containing therapy, that is, looking at long-term benefit, whereas TRYPHAENA explored the relationship between TOP2A amplification and pCR rate with anthracycline-containing treatment and analyzes tumor response as a shorter-term response measure.